TY - JOUR
T1 - Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
AU - Verspoor, F. G. M.
AU - Mastboom, M. J. L.
AU - Hannink, G.
AU - Maki, R. G.
AU - Wagner, A.
AU - Bompas, E.
AU - Desai, J.
AU - Italiano, A.
AU - Seddon, B. M.
AU - van der Graaf, W. T. A.
AU - Blay, J. Y.
AU - Brahmi, M.
AU - Eberst, L.
AU - Stacchiotti, S.
AU - Mir, O.
AU - van de Sande, M. A. J.
AU - Gelderblom, H.
AU - Cassier, P. A.
PY - 2019
Y1 - 2019
N2 - Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1–80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1–2 (89%). Five patients experienced grade 3–4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.
AB - Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1–80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1–2 (89%). Five patients experienced grade 3–4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073095561&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31601938
U2 - https://doi.org/10.1038/s41598-019-51211-y
DO - https://doi.org/10.1038/s41598-019-51211-y
M3 - Article
C2 - 31601938
SN - 2045-2322
VL - 9
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 14551
ER -